Aprea Therapeutics, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023; filed August 10, 2023. Aprea is a clinical-stage oncology company with no approved products or product-sales revenue.
Business context and outlook
The company’s focus is precision oncology through synthetic lethality following its 2022 acquisition of Atrin and discontinuation of active development of its legacy p53 programs. Lead candidate ATRN-119 is in a Phase 1/2a study in advanced solid tumors; management anticipated initial tolerability and pharmacokinetic data in Q1 2024. ATRN-1051, a preclinical WEE1 inhibitor, was expected to have an IND filed by year-end 2023. These are forward-looking targets, not assured outcomes.
Financial highlights
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Grant revenue | $249,688 | $0 | $249,688 | $0 |
| Research and development | $2.20 million | $6.81 million | $3.46 million | $10.90 million |
| General and administrative | $1.70 million | $15.63 million | $5.06 million | $19.62 million |
| Total operating expenses | $3.90 million | $98.47 million | $8.52 million | $106.54 million |
| Net loss | $3.26 million | $98.26 million | $7.64 million | $106.20 million |
| Operating cash used | Not separately presented | Not separately presented | $6.20 million | $14.40 million |
The 2022 comparison is substantially affected by the $76.0 million Atrin acquired in-process research and development charge and unusually high noncash stock-based compensation from accelerated vesting connected with the acquisition. The filing reports no product revenue; conventional gross margins are not meaningful.
At June 30, 2023, cash and cash equivalents were $27.69 million, with an additional $40,180 of restricted cash. Total assets were $28.68 million; current and total liabilities were $3.95 million, comprising accounts payable and accrued expenses. The filing reports no debt. Management estimated cash would fund operations and capital needs into Q4 2024, subject to assumptions; it expects to need additional financing thereafter.
For the first half, financing provided $5.14 million net: approximately $4.9 million from a February public offering of 1.05 million shares and $0.3 million net from ATM sales. Operating cash use plus financing resulted in a $1.06 million decrease in cash and cash equivalents. Accumulated deficit was $301.44 million at period-end. No meaningful profitability or margin trend is available because the company remains development-stage and loss-making.
Material changes, risks and unusual items
- Compared with the prior-year period, operating expenses and net loss fell sharply, principally because the 2022 period included Atrin acquisition-related IPR&D expense and accelerated stock-based compensation. Current-period R&D includes ATRN-119 clinical trial and ATRN-1051 enabling-study costs.
- The company’s existing cash runway estimate depends on uncertain development costs and financing conditions. It warns that it may need to reduce or curtail development if additional funds are unavailable; equity financing could dilute shareholders, and financing may not be available on acceptable terms.
- The business is substantially dependent on ATRN-119. Clinical efficacy and safety remain unproven; early-stage results may not predict later outcomes, and patient enrollment, regulatory review, manufacturing, and reliance on a single third-party manufacturer pose risks.
- In February 2023, Aprea effected a 1-for-20 reverse stock split; presented share and per-share figures are retrospectively adjusted. Shares outstanding were 3,731,571 at June 30 and 3,736,673 at August 10, 2023.
- On July 6, 2023, the common stock transferred from Nasdaq Global Select Market to Nasdaq Capital Market. The company disclosed no material legal proceedings, no recorded provision for contingent losses, and no material off-balance-sheet arrangements. Management reported disclosure controls effective as of June 30.
- A contingent value right relates to potential proceeds from disposition of legacy assets; its reported value was de minimis at June 30, 2023. The company disclosed approximately $0.1 million of remaining Sweden-related severance liability.
Important facts for investors to verify
- Whether ATRN-119 enrollment and the expected Q1 2024 data timing remain on track, and what the eventual safety and pharmacokinetic results show.
- Whether ATRN-1051’s IND-enabling work supports the stated year-end 2023 filing target.
- Whether cash use, trial costs, and new financing needs remain consistent with management’s Q4 2024 runway estimate; also verify financing capacity under the disclosed Form S-3 public-float limitation.
- The scope of dilution from future capital raises and the remaining preferred shares potentially convertible into common stock.
- Any changes in manufacturing arrangements, clinical enrollment, Nasdaq listing compliance, or risks associated with the company’s dependence on ATRN-119.